Problem.

Demonstrating efficacy is challenging with CNS therapeutics.

Only

Phase 1 to FDA approval

Less than

as likely as other therapeutic areas

And

as likely to fail in phase 3

CNS diseases are often complex, poorly defined, and difficult to measure. Also, patients are known to exhibit highly differential responses to CNS therapeutics, highlighting the need for patient measurement and stratification.

Solution.

Objective and automated measurement using multimodal AI enhances signal detection.

Increased

power.

Deliberate helps clinical trial sponsors achieve enhanced endpoint reliability, reduced sample size, faster completion, and lower cost.

Comprehensive measurement.

Our platform captures and analyzes signs beyond what a human clinician can perceive, including accurate side effect quantification.

Precision enrollment & enrichment.

With Deliberate, sponsors can screen and verify patients, capture validated baseline measures, and even perform patient enrichment via a companion Dx.